Search Results
Your search for ,iII matches 9602 pages
Showing 8801 - 8850Impressive Results With Daratumumab Plus Lenalidomide/Dexamethasone in Multiple Myeloma
The anti-CD38 monoclonal antibody daratumumab (Darzalex) took center stage among multiple myeloma studies presented at the 57th American Society of Hematology Annual Meeting and Exposition. In relapsed/refractory patients, daratumumab plus lenalidomide (Revlimid)/dexamethasone yielded an 81%...
National Cancer Database Study Indicates Racial Differences in Neoadjuvant Chemotherapy Use in Women With Breast Cancer
In a study reported in the Journal of Clinical Oncology, Killelea et al found that chemotherapy, particularly neoadjuvant chemotherapy, was more frequently given to black, Hispanic, and Asian women vs white women with stage I to III breast cancer, with the difference largely attributable to more...
Adding Ibrutinib to Bendamustine/Rituximab May Increase Progression-Free Survival in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
In the phase III HELIOS trial reported in The Lancet Oncology, Chanan-Khan et al found that the addition of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica) to bendamustine (Treanda)/rituximab (Rituxan) increased progression-free survival in patients with chronic lymphocytic ...
Study Reports Improved Survival With Lapatinib and CapeOx in Asian and Younger Patients With HER2-Positive Advanced Gastroesophageal Adenocarcinoma
In a phase III trial (TRIO-013/LOGiC) reported in the Journal of Clinical Oncology, Hecht et al found that the addition of lapatinib (Tykerb) to capecitabine-oxaliplatin (CapeOx) in patients with previously untreated HER2-amplified advanced gastroesophageal adenocarcinoma did not improve overall...
Patient-Reported Outcomes With Adjuvant Anastrozole vs Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ
As reported in The Lancet and at the recent San Antonio Breast Cancer Symposium, Ganz et al found differences in patient-reported outcomes with anastrozole vs tamoxifen in the phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 trial in postmenopausal women with hormone...
Jack Cuzick, PhD, FMedSci, on DCIS Recurrence Rates: Anastrozole vs Tamoxifen
Jack Cuzick, PhD, FMedSci, of Queen Mary, University of London, discusses his phase III study on postmenopausal women with DCIS who had similar outcomes whether they took tamoxifen or anastrozole for 5 years after surgery. (Abstract S6-03)
Hans Wildiers, MD, PhD on the TH3RESA Study: Final OS Results
Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously treated HER2-positive metastatic breast cancer (Abstract S5-05).
Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study (French Language Version) 
Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses in French a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with advanced Hodgkin lymphoma (Abstract 577).
Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study
Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with advanced Hodgkin lymphoma (Abstract 577). To see the French language version of this video, please click here.
ESMO Asia 2015: Results From the KEYNOTE-010 Trial Show Pembrolizumab Benefit in Patients With NSCLC
More patients with advanced non–small cell lung cancer (NSCLC) could benefit from pembrolizumab (Keytruda), said Roy Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven. Dr. Herbst presented promising results from the pivotal phase...
ESMO Asia 2015: Immunotherapy and Targeted Therapy Provide New Options for Difficult-to-Treat Head and Neck Cancer
Novel strategies are being explored for difficult-to-treat and advanced head and neck cancer—the most heterogeneous group of malignancies that are generally associated with poor survival—and encouraging results have been presented in two trials at the first European Society for Medical...
ESMO Asia 2015: Afatinib a Better Choice for EGFR-Mutated Lung Cancer in First-Line Treatment
Patients with epidermal growth factor receptor (EGFR)-activating mutations in advanced lung cancer seem to benefit more from afatinib (Gilotrif) than gefitinib (Iressa) as first-line treatment, Park et al reported in a study (Abstract LBA2) presented at the European Society for Medical Oncology...
Adding Ibrutinib to Bendamustine/Rituximab Increases Progression-Free Survival in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
In the phase III HELIOS trial, reported in The Lancet Oncology, Chanan-Khan et al found that adding the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) to bendamustine (Treanda)/rituximab (Rituxan) increased progression-free survival in patients with chronic lymphocytic leukemia or...
Similar Outcomes Reported With Surgery vs Definitive Concurrent Chemoradiotherapy in Resectable Stage III NSCLC
Findings in an early-terminated German phase III trial (ESPATUE), reported in the Journal of Clinical Oncology by Eberhardt et al, indicate similar outcomes with surgery vs definitive concurrent chemoradiotherapy after induction chemotherapy and chemoradiotherapy in patients with resectable stage...
Treatment Trends in Stage II and III Colorectal Cancer in the United States
As reported by Murphy et al in the Journal of the National Cancer Institute, an analysis of Surveillance, Epidemiology, and End Results (SEER) data from patients with stage II or III colorectal cancer indicated that the use of adjuvant chemotherapy in colon cancer declined slightly between 2005 and ...
Moore Scoring System Helps Identify Women With Advanced Cervical Cancer Who May Not Benefit From Bevacizumab
Previously published reports from the randomized phase III Gynecologic Oncology Group (GOG) protocol 240 clinical trial showed that adding bevacizumab (Avastin) to a chemotherapy regimen of paclitaxel plus cisplatin or topotecan significantly increased overall survival and progression-free survival ...
FDA Allows Marketing of Cooling Cap to Reduce Hair Loss During Chemotherapy
The U.S. Food and Drug Administration has cleared the first cooling cap to reduce hair loss in female breast cancer patients undergoing chemotherapy for marketing in the United States. Hair loss is a common side effect of certain types of chemotherapy, commonly associated with the treatment of...
SABCS 2015: Phase III BELLE-2 Trial Meets Primary Endpoint of Progression-Free Survival
Among women with locally advanced or metastatic hormone receptor–positive breast cancer that was resistant to hormone therapy, those who had mutated PIK3CA detected in their blood benefited from a combination of the investigational PI3K inhibitor buparlisib and fulvestrant (Faslodex),...
SABCS 2015: Ado-Trastuzumab Emtansine Improved Overall Survival for Heavily Pretreated Patients With HER2-Positive Breast Cancer
Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib [Tykerb]), median overall survival was increased for those treated with ado-trastuzumab emtansine (aka T-DM1...
SABCS 2015: No Significant Difference in Recurrence Rates Among Women With Ductal Carcinoma in Situ Taking Anastrozole or Tamoxifen
Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for 5 years after surgery, but women in the two groups had different side effects, according to results from the phase III...
SABCS 2015: Patients With Ductal Carcinoma in Situ Receiving Anastrozole Reported Symptoms Different From Those in Patients Receiving Tamoxifen
Analysis of patient-reported outcomes, a secondary endpoint of the phase III NSABP B-35 clinical trial, in which anastrozole and tamoxifen were compared in postmenopausal women with ductal carcinoma in situ (DCIS) who underwent lumpectomy plus radiotherapy, found that there were no differences in...
SABCS 2015: Pathologic Complete Response to Presurgery Chemotherapy Improves Survival for Patients With Triple-Negative Breast Cancer
Patients with stage II or stage III triple-negative breast cancer who had a pathologic complete response (pCR) after presurgery chemotherapy had increased event-free and overall survival compared with those who had more than minimal residual invasive disease at surgery following presurgery...
SABCS 2015: Women With Luminal A Breast Cancer Did Not Benefit From Adjuvant Chemotherapy in Phase III Trial
Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates, regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III Dutch Breast Cancer Cooperative Group (DBCG77B) clinical trial...
SABCS 2015: Capecitabine Improved Outcomes for Breast Cancer Patients With Residual Disease After Presurgery Chemotherapy
Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer...
SABCS 2015: Denosumab Improves Disease-Free Survival for Postmenopausal Patients With Hormone Receptor–Positive Breast Cancer
Adding denosumab (Xgeva) to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal patients with early-stage, hormone receptor–positive breast cancer, according to results from the phase III ABCSG-18 clinical trial presented at the 2015 San Antonio Breast...
Improved Overall Survival With Addition of Nanoliposomal Irinotecan to Fluorouracil/Leucovorin in Metastatic Pancreatic Cancer
In the phase III NAPOLI-1 trial reported in The Lancet, Wang-Gillam et al found that the addition of nanoliposomal irinotecan (Onivyde) to fluorouracil (5-FU) and folinic acid (leucovorin) resulted in improved overall survival in patients with metastatic pancreatic ductal cancer who had received...
ASH 2015: Updated Results of Phase III Tourmaline-MM1 Study of Ixazomib in Multiple Myeloma
In a study presented by Moureau et al at the 57th American Society of Hematology (ASH) Annual Meeting, ixazomib (Ninlaro), a recently approved oral proteasome inhibitor, significantly extended progression-free survival for patients with relapsed and/or refractory multiple myeloma (Abstract 727)....
European Trial Shows Front-Line Addition of Nintedanib to Standard Chemotherapy Improves Progression-Free Survival in Advanced Ovarian Cancer
In a European phase III trial (AGO-OVAR 12) reported in The Lancet Oncology, du Bois et al found that adding the antiangiogenic multikinase inhibitor nintedanib (Ofev) to carboplatin/paclitaxel improved progression-free survival in patients with newly diagnosed ovarian cancer. Gastrointestinal...
ASH 2015: Ibrutinib Data Underscore Promise of Targeted Therapies as First-Line Approach for Patients With Chronic Lymphocytic Leukemia
A presentation by Tedeschi et al at the 57th American Society of Hematology (ASH) Annual Meeting outlined results of the phase III RESONATE TM-2 study of ibrutinib (Imbruvica) vs chlorambucil (Leukeran) in patients aged 65 years and older with treatment-naive chronic lymphocytic leukemia/small...
ASH 2015: Combination Therapy With Idelalisib Improves Progression-Free Survival vs Bendamustine/Rituximab Alone in Relapsed/Refractory CLL
In a phase III study to be presented by Zelenetz et al at the 57th American Society of Hematology Annual Meeting, idelalisib (Zydelig) plus bendamustine (Treanda) and rituximab (Rituxan), or BR, proved superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)...
Better Invasive Disease–Free Survival With Epirubicin/Cyclophosphamide and Docetaxel vs Epirubicin/Docetaxel and Capecitabine in Breast Cancer
In a Spanish phase III trial (GEICAM/2003-10) reported in the Journal of Clinical Oncology, Martín et al found that invasive disease–free survival was improved with adjuvant epirubicin/cyclophosphamide (EC) followed by docetaxel (EC-T) vs epirubicin/docetaxel followed by capecitabine...
ASH 2015: Midostaurin Improves Survival in Patients With FLT3-Mutated Acute Myeloid Leukemia Aged 18–60
A study presented by Stone et al at the 57th American Society of Hematology (ASH) Annual Meeting described a phase III trial of the first targeted therapy for genetically defined subset of patients with acute myeloid leukemia and its improvement of their survival (Abstract 6). Acute myeloid...
Reduced Nonrelapse Mortality With Busulfan/Fludarabine vs Busulfan/Cyclophosphamide for Stem Cell Transplantation in Acute Myeloid Leukemia
In a phase III trial reported in The Lancet Oncology, Rambaldi et al found that a myeloablative conditioning regimen of busulfan/fludarabine was associated with reduced nonrelapse mortality vs busulfan/cyclophosphamide in patients with acute myeloid leukemia (AML) undergoing allogeneic...
Benefit of Maintenance Bevacizumab-Erlotinib vs Bevacizumab After Bevacizumab-Based Induction Therapy in Metastatic Colorectal Cancer
As reported by Tournigand et al in The Lancet Oncology, final analysis of the phase III GERCOR DREAM (OPTIMOX3) trial suggested a benefit of maintenance bevacizumab (Avastin)-erlotinib vs bevacizumab after bevacizumab-based induction therapy in patients with previously untreated metastatic...
Study Finds Better Outcome With Melphalan Plus ASCT vs Chemotherapy Plus Lenalidomide Consolidation in Multiple Myeloma
In a phase III trial reported in The Lancet Oncology, Gay et al found that progression-free survival was shorter with lenalidomide (Revlimid) plus chemotherapy vs high-dose melphalan plus autologous stem cell transplantation in transplant-eligible patients with multiple myeloma, with no significant ...
Prognostic Model for Survival in Advanced-Stage Mycosis Fungoides and Sézary Syndrome
As reported by Scarisbrick et al in the Journal of Clinical Oncology, a Cutaneous Lymphoma International Consortium study in a large population of patients with advanced-stage mycosis fungoides and Sézary syndrome has identified independent prognostic factors for overall survival that can be ...
FDA Approves Single-Agent Nivolumab for Previously Untreated BRAF Wild-Type Advanced Melanoma
The U.S. Food and Drug Administration (FDA) today approved the programmed cell death protein 1 (PD-1) inhibitor nivolumab (Opdivo) as a single agent for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. Clinical Trial Results The approval is based on data...
10-Year Results of MOSAIC Trial Show Continued Survival Benefit of Adjuvant FOLFOX4 in Stage III Colon Cancer
Ten-year results of the MOSAIC trial, reported in the Journal of Clinical Oncology by André et al show a continued overall survival benefit with adjuvant FOLFOX4 (fluorouracil [5-FU] leucovorin plus oxaliplatin) vs 5-FU/leucovorin in patients with stage III colon cancer and in the entire...
‘Substantial Number’ of Patients Requiring Palliative Radiotherapy for Stage IV NSCLC Are Overtreated
An analysis of data from 46,803 patients with stage IV non–small cell lung cancer (NSCLC) who received palliative chest radiation therapy found that 49% received radiotherapy for longer than 15 fractions and 28% received more than 25 fractions. This treatment pattern “is inconsistent...
Increasing Use of Preoperative Breast MRI Linked to Increased Postdiagnostic Imaging and Biopsy, Mastectomy, and Surgery Delay
In a Canadian population-based study reported in JAMA Oncology, Arnaout et al found that breast magnetic resonance imaging (MRI) is increasingly used in preoperative evaluation of women with breast cancer and that its use is associated with increased likelihood of confirmatory breast imaging,...
No Difference in Overall Survival, Poorer Relapse-Free Survival With Adjuvant Intermittent vs High-Dose Interferon Alfa-2b in Stage III Melanoma
The final analysis of a European Dermatologic Cooperative Oncology Group phase III trial, reported in the Journal of Clinical Oncology by Mohr et al, showed that adjuvant intermittent vs standard high-dose intravenous interferon alfa-2b was associated with no difference in overall survival but...
Dexamethasone Reduces Pain Flare After Palliative Radiotherapy for Bone Metastases
In a Canadian phase III trial reported in The Lancet Oncology, Chow et al found that prophylactic dexamethasone reduced the incidence of radiation-induced pain flare compared with placebo in patients receiving palliative radiotherapy for bone metastases. Study Details In this double-blind trial,...
Lenalidomide Plus Rituximab Appears Promising as First-Line Therapy for Mantle Cell Lymphoma
Mantle cell lymphoma, which is characterized by CD5-positive, CD23-negative follicular mantle B cells with t(11:14)(q13;q32) translocation and cyclin D1 overexpression, is generally incurable and associated with a median survival of between 4 and 5 years. Although front-line treatment for mantle...
Phase III Trials Fail to Show Noninferiority of Surgical Outcome for Laparoscopic vs Open Resection in Rectal Cancer
Two phase III trials, reported in JAMA by Fleshman et al and Stevenson et al, failed to show noninferiority of surgical outcome for laparoscopic vs open resection in patients with rectal cancer. ACOSOG Z6051 Trial In the American College of Surgeons Oncology Group (ACOSOG) Z6051 trial, reported...
No Significant Survival Improvement With Etirinotecan Pegol vs Physician’s Choice in Heavily Pretreated Advanced Breast Cancer
In the phase III BEACON trial reported in The Lancet Oncology, Perez et al found that etirinotecan pegol was not associated with a significant increase in overall survival compared with physician’s choice of treatment in women with locally recurrent or metastatic breast cancer previously...
Chemoradiotherapy Survival Benefit in Elderly Patients With Limited-Stage SCLC
In a population-based study reported in the Journal of Clinical Oncology, Corso et al found that chemoradiotherapy was associated with an overall survival benefit vs chemotherapy in elderly patients with limited-stage small cell lung cancer (SCLC). Study Details The study involved National Cancer ...
Reduced Relapse but No Quality-of-Life Benefit With ATRA/Arsenic Trioxide vs ATRA/Idarubicin in Acute Promyelocytic Leukemia
In a UK-based phase III trial (AML17) reported in The Lancet Oncology, Burnett et al found that a chemotherapy-free regimen of arsenic trioxide plus all-trans retinoic acid (ATRA) did not improve quality of life, the primary endpoint, vs ATRA plus idarubicin in patients with acute promyelocytic...
Telotristat Etiprate Shows Clinical Benefit in Treating Carcinoid Syndrome in Cancer Patients When Added to Standard of Care
Lexicon Pharmaceuticals, Inc's telotristat etiprate was shown to have clinical benefit in treating carcinoid syndrome in cancer patients not adequately controlled by long-acting somatostatin analog therapy, the current standard of care, according to data from the phase III TELESTAR study presented...
FDA Approves Talimogene Laherparepvec for Unresectable Recurrent Melanoma
The U.S. Food and Drug Administration (FDA) has approved the biologics license application for talimogene laherparepvec (Imlygic), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma...
ASTRO 2015: The Addition of 24 Months of Daily Antiandrogen Therapy Improves Overall Survival Following Recurrence After a Radical Prostatectomy
Prostate cancer patients who face recurrence after radical prostatectomy have better overall survival rates with a combination of salvage radiation therapy and 24 months of antiandrogen therapy than with radiation therapy alone, according to research (Abstract LBA5) presented by Shipley et al on...
